<DOC>
	<DOC>NCT02167594</DOC>
	<brief_summary>This study will evaluate 18F-AV-1451 for brain imaging of tau in subjects with progressive supranuclear palsy (PSP), corticobasal degeneration (CBD) and healthy volunteers.</brief_summary>
	<brief_title>Tau Imaging in Subjects With Progressive Supranuclear Palsy, Corticobasal Degeneration and Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Paralysis</mesh_term>
	<mesh_term>Supranuclear Palsy, Progressive</mesh_term>
	<criteria>Cognitively Healthy Volunteers Minimental state examination (MMSE) ≥ 28 No history of cognitive decline or parkinsonian motor disorder CBD and PSP subjects Able to walk 10 steps with minimal assistance MMSE ≥ 14 and ≤ 30 Subject has a reliable study partner who agrees to accompany subject to visits and spends at least 5 hours per week with the subject PSP subjects only Meet National Institute of Neurological Disorders and Stroke Society for Progressive Supranuclear Palsy (NINDSSPSP) probable or possible PSP criteria as modified for the Neuroprotection and Natural History Parkinson Plus Syndromes (NNIPPS) clinical trial CBD subjects only Meets 2013 consensus criteria for possible or probably corticobasal degeneration, corticobasal syndrome (CBS) subtype All subjects Have evidence of structural abnormalities such as vascular disease, large strokes or severe white matter disease or other mass lesion on screening MRI Claustrophobia Current clinically significant cardiovascular disease or clinically significant abnormalities on screening ECG (e.g. QTC&gt;450 msec) Have a history of risk factors for Torsades de Pointes (e.g. heart failure, hypokalemia, family history of long QT syndrome) Have a current clinically significant infectious disease, endocrine or metabolic disease, pulmonary, renal or hepatic impairment, or cancer Females of childbearing potential who are not surgically sterile, not refraining from sexual activity or not using reliable methods of contraception Have received or participated in a trial with investigational medications in the past 30 days Have had a nonstudy related radiopharmaceutical imaging or treatment procedure within 7 days prior to the study imaging session Have a history of neuroleptic use for a prolonged period of time or within the past 6 months PSP and CBD subjects Have evidence of amyloid deposition Meet National Institute on AgingAlzheimer's Association criteria for probable Alzheimer's Disease Have any other neurological condition other than CBS or PSP that could account for cognitive or motor deficits Serum or plasma progranulin level less than one standard deviation below the normal subject mean for the laboratory performing the assay Have a highrsk family history suggestive of TDP43 pathology or known mutations</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>